^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Germ Cell Tumors

    21h
    BiomarkCBT: Biomarkers of Brain Injury in Children With Brain Tumors (clinicaltrials.gov)
    P=N/A, N=560, Recruiting, Uppsala University
    New trial
    1d
    A Histological Conundrum With a Distinctive Biochemical Marker: A Case Report of Primary Pulmonary Choriocarcinoma. (PubMed, Cureus)
    This case illustrates the histopathological difficulties in diagnosing PPC and the utility of serum hCG measurement in the detection of PPC. Serum hCG measurement is useful as an initial investigation for possible PPC in patients with non-small cell lung tumors, which should be followed by immunohistochemical staining for markers of choriocarcinoma.
    Journal
    |
    PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NKX2-1 (NK2 Homeobox 1) • SALL4 (Spalt Like Transcription Factor 4) • GATA3 (GATA binding protein 3) • SYP (Synaptophysin) • TCF4 (Transcription Factor 4)
    1d
    Preclinical Evaluation and First-in-Human Imaging with 18F-NOTA-R49: A Comparative Analysis versus 18F-FDG PET/CT in Various Cancer Patients. (PubMed, Mol Pharm)
    18F-NOTA-R49 demonstrates high affinity and specificity and excellent tumor-targeting properties. It shows better diagnostic efficacy than 18F-FDG in various malignant tumors, indicating a significant clinical translation potential.
    P1 data • Preclinical • Journal • First-in-human
    |
    FAP (Fibroblast activation protein, alpha)
    2d
    Liquid Biopsy in Germ Cell Tumors (clinicaltrials.gov)
    P=N/A, N=200, Not yet recruiting, Medical University of Graz
    New trial • Liquid biopsy
    3d
    Study on the Correlation Between Mutation Types of BRCA Gene-Positive Epithelial Ovarian Cancer and Clinical Baseline Characteristics, Pathological Features, and Prognosis (ChiCTR2600116755)
    P=N/A, N=80, Not yet recruiting, Linyi Tumor Hospital; Linyi Tumor Hospital
    New trial
    |
    BRCA2 (Breast cancer 2, early onset) • WT1 (WT1 Transcription Factor) • BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    BRCA mutation
    3d
    Torametinib for the Treatment of Recurrent/Refractory Pediatric Tumors (ChiCTR2500114659)
    P4, N=28, Not yet recruiting, The First Affiliated Hospital,Sun Yat-sen University; The First Affiliated Hospital, Sun Yat-sen University
    New P4 trial
    |
    BRAF (B-raf proto-oncogene) • NF1 (Neurofibromin 1)
    |
    BRAF V600 • RAS mutation
    |
    Loqtorzi (toripalimab-tpzi)
    3d
    A prospective, single-arm, single-center study of toripalimab combined with chemotherapy in second-line treatment of advanced germ cell tumors (ChiCTR2500112832)
    P2, N=34, Not yet recruiting, Shandong First Medical University Affiliated Cancer Hospital; Shandong First Medical University Affiliated Cancer Hospital
    New P2 trial
    |
    cisplatin • Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel • ifosfamide
    4d
    Postmenopausal Stage IV Ovarian Yolk Sac Tumor With Neuroendocrine Features: Report of a Rare Case. (PubMed, Anticancer Res)
    This case illustrates a particularly rare and aggressive presentation of ovarian YST in a postmenopausal patient. Early recognition, accurate pathological characterization, and individualized treatment are essential, although prognosis remains poor in this setting. Reporting such cases is crucial to improve understanding and management of these exceptional tumors.
    Journal
    |
    CHGA (Chromogranin A)
    |
    cisplatin • etoposide IV • bleomycin
    5d
    Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic (clinicaltrials.gov)
    P2, N=157, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2028 | Trial primary completion date: Dec 2025 --> Dec 2028
    Trial completion date • Trial primary completion date • Tumor mutational burden
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab)
    5d
    Simultaneous occurrence of bilateral retroperitoneal neuroblastoma and bifocal malignant mixed germ cell tumor in a pediatric patient with 16p11.2 microdeletion syndrome: a case report. (PubMed, Front Endocrinol (Lausanne))
    Furthermore, a heterozygous missense variant in the ALK gene (p. Arg1275Gln) was identified.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • ARG1 (Arginase 1)
    6d
    Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    LDH elevation
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)